Trial · NCT04530058
The Effects of Metformin on Morbidity and Mortality in Elderly Patients
NCT04530058, Phase 2, Not yet recruiting, Hamilton Health Sciences Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Metformin on Morbidity and Mortality in Elderly Patients. Trials, record NCT04530058. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04530058
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Metformin on Morbidity and Mortality in Elderly Patients
- NCT number
- NCT04530058
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 250 participants, estimated
- Lead sponsor
- Hamilton Health Sciences Corporation
- Conditions
- Burns
- Interventions
- Metformin, Placebos
- First posted
- 2020-08-28
- Last updated
- 2024-10-02
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Record mortality | Acute hospitalization up to one year post burn. | Patient mortality will be recorded during hospitalization and outpatient follow-ups. |
| Primary | Record the episodes of sepsis. | daily until discharge (1-4 months post admission depending on severity of injury)] | Patients will be assessed daily for episodes of sepsis. The total number of episodes over the course of hospital stay will be recorded. |
| Primary | Record episodes of infection. | daily until discharge (1-4 months post admission depending on severity of injury)] | Patients will be assessed daily for episodes of infection. The total number of episodes over the course of hospital stay will be recorded. |
| Primary | Record episodes of pneumonia. | daily until discharge (1-4 months post admission depending on severity of injury)] | Patients will be assessed daily for episodes of infection. The total number of episodes over the course of hospital stay will be recorded. |
| Primary | Organ function - Alkaline phosphatase (ALP) | twice weekly until discharge (1-4 months post admission depending on severity of injury)] | Organ function will be assessed by measuring the biomarker: ALP (U/L). |
| Primary | Organ function - Alanine transaminase (ALT) | twice weekly until discharge (1-4 months post admission depending on severity of injury)] | Organ function will be assessed by measuring the biomarker: ALT (U/L). |
| Primary | Organ function - Bilirubin | twice weekly until discharge (1-4 months post admission depending on severity of injury)] | Organ function will be assessed by measuring the biomarker: bilirubin (umol). |
| Primary | Organ function - Blood Urea Nitrogen (BUN) | twice weekly until discharge (1-4 months post admission depending on severity of injury)] | Organ function will be assessed by measuring the biomarker: BUN (mmol). |
| Primary | Organ function - Creatinine | twice weekly until discharge (1-4 months post admission depending on severity of injury)] | Organ function will be assessed by measuring the biomarker: creatinine (umol/L). |
| Secondary | Measures of steady-state resting energy expenditure (REE) | weekly until discharge if a patient is intubated and ventilated (1-4 months post admission depending on severity of injury)] | Metabolic response to injury and illness can be studied by measuring steady-state resting energy expenditure. Hypermetabolism is used as a secondary endpoint as stress-induced diabetes is associated with inflammation and hypermetabolism. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04530058
GET https://conductscience.org/api/trials/v1/NCT04530058/registered